Investigator-sponsored trial of efficacy and tolerability of cabozantinib (cabo) at lower dose: A dose-finding study in men with castration-resistant prostate cancer (CRPC) and bone metastases.
Richard J. Lee(La Roche College), Matthew R. Smith(Harvard University), M. Dror Michaelson(Harvard University), Daniel A. Haber(Howard Hughes Medical Institute), David T. Miyamoto(Broad Institute), Jonathan Goldin(UCLA Health), Philip J. Saylor(Massachusetts General Hospital), Shyamala Maheswaran(Massachusetts General Hospital), Carol Gurski(University of California, Los Angeles), S. Michael Rothenberg(Pfizer (United States))
Cited by 2
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Isolation of rare circulating tumour cells in cancer patients by microchip technology
|Nature|2007|3.5k
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
|New England Journal of Medicine|2010|3.5k